GSK submitted the same Blenrep clinical trial data to global regulators and the FDA, but received a slightly more limited regulatory approval in the U.S. In an interview during the annual meeting of the American Society of Hematology, GSK oncology executive Hesham Abdullah explained what else the FDA wants from Blenrep clinical trials.
The post At ASH, GSK’s Top Cancer Exec Discusses the FDA’s Different Take on Multiple Myeloma Drug Blenrep appeared first on MedCity News.
